O
KALV

OrbiMed’s KalVista Pharmaceuticals KALV Stock Holding History

OrbiMed’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-94,400
Closed -$1.9M – 142
2026
Q1 		$1.9M Sell
94,400
-288,000
-75% -$4.64M 0.04% 107
2025
Q4 		$6.18M Buy
+382,400
New +$5.06M 0.13% 89
2022
Q4 		– Sell
-1,042,000
Closed -$15.1M – 123
2022
Q3 		$15.1M Buy
1,042,000
+856,600
+462% +$12M 0.28% 74
2022
Q2 		$1.82M Buy
+185,400
New +$2.05M 0.03% 133
2020
Q2 		– Sell
-420,641
Closed -$3.22M – 144
2020
Q1 		$3.22M Buy
420,641
+260,100
+162% +$3.51M 0.05% 116
2019
Q4 		$2.86M Buy
160,541
+121,808
+314% +$1.59M 0.04% 114
2019
Q3 		$449K Buy
+38,733
New +$626K 0.01% 114
2019
Q2 		– Sell
-90,500
Closed -$2.59M – 134
2019
Q1 		$2.59M Buy
+90,500
New +$1.96M 0.04% 115

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

OrbiMed's KALV Position: Q2 2026 in Review

OrbiMed sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 94,400 shares — an estimated $1.9M sold.

OrbiMed first reported a position in KALV in Q1 2019 and held it in 8 quarters. The position peaked at $15.1M in Q3 2022. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • OrbiMed reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • OrbiMed sold 94,400 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.9M.
  • OrbiMed first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 8 quarters.
  • OrbiMed's KalVista Pharmaceuticals position peaked at $15.1M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.